Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

BACKGROUND: Immunotherapy combined with platinum-based chemotherapy is now the standard first-line treatment for non-small cell lung cancer (NSCLC) patients. However, limited evidence exists to show the efficacy of immunotherapy plus taxanes for patients who have progressed after platinum-based chem...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ther Adv Med Oncol
Prif Awduron: Zhang, Fan, Huang, Di, Zhao, Lei, Li, Tao, Zhang, Sujie, Zhang, Guoqing, Yuan, Fang, Zhang, Jie, Zhang, Yuzi, Zhao, Zhengyi, Cui, Longgang, Zhao, Jing, Wang, Guoqiang, Cai, Shangli, Bai, Yuezong, Wang, Jinliang, Hu, Yi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: SAGE Publications 2020
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7338650/
https://ncbi.nlm.nih.gov/pubmed/32670420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920936882
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg